Latest Commercialization News

Korab Resources reports significant gold and base metals exploration progress at its Rum Jungle Project, alongside innovative mining method evaluations and ongoing legal challenges to key lease renewals.

Robex Resources has reached a pivotal milestone at its Kiniéro Gold Project in Guinea by delivering first ore to the mill, setting the stage for first gold production expected this month.

Janus Electric reports strong progress in truck conversions and US export orders while navigating a delay in expected EVUNI investment funding, secured by interim asset-backed financing.

Charter Hall Long WALE REIT has announced an ordinary unfranked quarterly distribution of AUD 0.06375 per security, payable in February 2026, alongside a Dividend Reinvestment Plan offering a 1% discount.

Medallion Metals has completed a Feasibility Study for its Ravensthorpe Gold Project, confirming robust economics and a clear pathway to near-term gold and copper production leveraging existing infrastructure in Western Australia.

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.

ABx Group has secured a new five-year exploration licence in northern Tasmania, expanding its rare earths tenure between key deposits and advancing its high-value rare earth product development.

Metallium Limited has resumed trading on the ASX following news of a significant collaboration and funding deal with a US partner to advance its critical-metals recovery technology.

Metallium Ltd has secured a strategic partnership with ElementUSA to deploy its Flash Joule Heating technology for recovering gallium and scandium from red mud in Louisiana, backed by US$10.1 million in non-dilutive funding. This collaboration positions Metallium at the forefront of the US critical minerals supply chain expansion.

4DMedical has locked in $30.2 million through an underwriting agreement ensuring full exercise of its listed options, lifting its cash reserves to $63.7 million and setting the stage for a pivotal year in commercialising its CT – VQ™ technology.

Artrya Limited has begun generating fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health in the U.S., marking a key commercial milestone for the AI-powered cardiac imaging platform.

Rhythm Biosciences has begun commercialising ColoSTAT®, its blood-based colorectal cancer diagnostic test, following an updated ISO15189, 2022 accreditation. The test offers a new option for symptomatic patients where stool-based screening is unsuitable.